VB19055 / Shenzhen Yangli Pharma - LARVOL DELTA

A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension (clinicaltrials.gov) - P2 | N=240 | Not yet recruiting | Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

New P2 trial • Cardiovascular • Hypertension

VB19055: A NOVEL ALDOSTERONE SYNTHASE INHIBITOR WITH IMPROVED SELECTIVITY AND EFFICACY (ACC 2026) - "We present VB19055 as a highly selective AS inhibitor with improved pharmacological properties compared to Baxdrostat. VB19055 shows higher selectivity, superior exposure, and stronger efficacy, supporting its potential in hypertension and other CVRM disorders. It is currently under clinical investigation in healthy volunteers."

Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypertension • Hypotension • Nephrology • Renal Disease • CYP11B1

VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

New P1 trial • Cardiovascular • Hypertension